Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
$6.98
+5.3%
$6.15
$4.66
$7.38
$114.65M0.816,933 shs15,084 shs
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
$1.36
+3.8%
$1.06
$0.77
$3.12
$112.35M0.98357,213 shs240,538 shs
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
$0.06
-2.4%
$0.06
$0.02
$0.07
$25.31M-0.78116,452 shs4,806 shs
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
$0.00
$0.50
$1.86
$105.76MN/A71,826 shs50,100 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-1.78%+6.08%+1.53%+25.57%+662,999,900.00%
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
+5.65%+12.93%+14.91%+13.91%-52.88%
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
-2.36%+3.33%+20.39%+55.00%+64.89%
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2.4721 of 5 stars
3.74.00.00.02.00.00.6
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
3.00
Buy$13.6795.80% Upside
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
3.40
Buy$8.67537.25% Upside
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
0.00
N/AN/AN/A
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OTLC, TBUFF, CRDL, and BHST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/2/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
5/5/2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$15.00
4/16/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
4/8/2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/7/2025
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
$27.70M4.14N/AN/A($1.08) per share-6.46
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/A$0.32 per shareN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
$70K361.63$0.02 per share3.12$0.03 per share2.07
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$12.56M-$0.50N/AN/AN/A-76.65%N/A-85.16%8/14/2025 (Estimated)
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$20.84M-$0.34N/AN/AN/AN/A-194.40%-129.07%7/14/2025 (Estimated)
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
-$7.90M-$0.01N/AN/AN/A-8.48%-3.09%N/A
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/A0.00N/AN/AN/AN/AN/AN/A

Latest OTLC, TBUFF, CRDL, and BHST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million
3/31/2025Q4 2024
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
-$0.12-$0.17-$0.05-$0.17$7.24 million$7.17 million
3/31/2025Q4 2024
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
-$0.08-$0.07+$0.01-$0.07N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/AN/AN/AN/AN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
N/AN/AN/AN/AN/A
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
N/AN/AN/AN/AN/A
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A
0.80
0.48
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
0.01
2.49
2.49
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
0.28
0.01
0.01
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
BioHarvest Sciences Inc. stock logo
BHST
BioHarvest Sciences
N/A16.43 millionN/AN/A
Cardiol Therapeutics Inc. stock logo
CRDL
Cardiol Therapeutics
2082.61 million78.27 millionNot Optionable
Oncotelic Therapeutics, Inc. stock logo
OTLC
Oncotelic Therapeutics
20408.29 million246.93 millionNot Optionable
Tribute Pharmaceuticals Canada Inc. stock logo
TBUFF
Tribute Pharmaceuticals Canada
N/A113.72 millionN/ANot Optionable

Recent News About These Companies

Valeo Pharma Inc. (VPHIF)
About Tribute.ca
Ron Canada Biography & Movies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioHarvest Sciences stock logo

BioHarvest Sciences NASDAQ:BHST

$6.98 +0.35 (+5.28%)
As of 12:44 PM Eastern

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.

Cardiol Therapeutics stock logo

Cardiol Therapeutics NASDAQ:CRDL

$1.36 +0.05 (+3.82%)
As of 01:20 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Oncotelic Therapeutics stock logo

Oncotelic Therapeutics OTCMKTS:OTLC

$0.06 0.00 (-2.36%)
As of 06/3/2025 12:51 PM Eastern

Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies. Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.

Tribute Pharmaceuticals Canada stock logo

Tribute Pharmaceuticals Canada OTCMKTS:TBUFF

Tribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.